.png)
Professor John Pimanda
University of New South Wales
$450,000
2025 - 2028
The Research
Chronic myelomonocytic leukemia (CMML) is a neoplasm with impaired blood production. Hypomethylating agents (HMA) are effective in 40-50%, but responses are temporary.
Here, we will apply state-of-the-art techniques that we have developed to explore molecular changes in CMML stem cells using patient samples collected before and during HMA therapy in clinical responders and non-responders to identify critical differences that can be leveraged to develop a prognostic assay and targeted therapies.
The team just published this manuscript (13/5/2025) which forms the basis for the investigations (identifying potential biomarkers of clinical response to hypomethylating agents in CMML) in Nature Communications.
share
.svg)
